FDA Approves Lilly’s New Breast Cancer Drug Combination
No Comments on FDA Approves Lilly’s New Breast Cancer Drug Combination
The U.S. FDA has approved Eli Lilly’s Inluriyo and Verzenio combination for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.